HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor
China‑based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has...
Deals
Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal
Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant is reportedly in exploratory talks...
Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033
China‑based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with Tianjin Jikun Pharmaceutical...
BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth
A leaked internal email from US major Bristol-Myers Squibb (BMS; NYSE: BMY) has recently surfaced...
GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B
China‑based GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) completed a successful initial public offering (IPO) on the...
Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity
Remedium Bio, Inc. (Remedium) announced a multi‑target R&D partnership with Eli Lilly & Co. (NYSE: LLY) to...
YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront
The AstraZeneca‑CICC Medical Industry Fund announced that it led a Series B financing round for China‑based...
Innovent Biologics & Cowell Health Forge Strategic Alliance to Boost Drug Access
Innovent Biologics Inc. (HKG: 1801) announced a strategic cooperation agreement with Cowell Health. The partnership is...
Qilu Pharmaceutical & FDSTC Announce Strategic Partnership to Boost China’s Biomedical Innovation
China‑based Qilu Pharmaceutical and the Foundation for the Development of Science and Technology in China (FDSTC),...
Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development
China‑based Corxel Pharmaceuticals (CORXEL) and WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), have...
Danaher Partners with Beckman to Advance Alzheimer’s Blood‑Biomarker Diagnosis
US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced that its operating subsidiary,...
Kexing Biopharm Secures Global Rights to Humanwell PuraCap’s Nintedanib
China‑listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell...
IASO Biotherapeutics & Cellbri Sign Global Cell‑Therapy Alliance
China‑based IASO Biotherapeutics and Shenzhen Cellbri Bio‑Innovation Technology Co., Ltd. announced a global strategic cooperation...
Sirnaomics Secures HK$138 M Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines
Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong Kong) Limited, a...
XWPharma Secures $205 M Valiloxybate Deal with Avadel
China‑based XWPharma Ltd. announced today that it has entered into an exclusive licensing agreement with...
Escugen and Huahui Health Form Exclusive Partnership to Develop First‑in‑Class ADC for Solid Tumors
Shanghai‑based Escugen and Beijing‑headquartered Huahui Health have announced a global, exclusive cooperation agreement to develop...
Gilead Terminates $2.3 B Collaboration With Kite Pharma Over Off‑the‑Shelf Cell Therapies
US-based Gilead Sciences’ (NASDAQ: GILD) subsidiary Kite Pharma has officially ended its $2.3 billion collaboration with Shoreline...
Hengrui Licenses HRS‑1893 to Braveheart Bio in $75 M Deal – Global Myosin Inhibitor
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced an exclusive licensing arrangement with...
Dongcheng Pharma to Spin‑Off Lannacheng for HK Main Board Listing – Radiopharma Focus
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) announced that it will spin off its...
Biocytogen, Merck Partner on Antibody‑Conjugated Lipid Nanoparticles
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has signed an evaluation...